ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Debt Repayment
Cash used to repay borrowings during the period.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment growth accelerates
Q1 FY2026 debt repayment of $4.06M (cash outflow) rose 100.0% year over year, ahead of the -103.7% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +50.2% a year.
Context
- Debt repayment amounted to 1.1% of revenue in FY2025, down 55.0 pp from a year earlier.
- Debt repayment increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +100.0% holds above the trailing-twelve-month pace of -103.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (10.16M) USD
- Year-over-year change
- -102.9%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.16M) | -102.9% |
| FY2024 | 2024-12-31 | 345.22M | +11607.3% |
| FY2023 | 2023-12-31 | (3M) | +0.0% |
| FY2022 | 2022-12-31 | (3M) | -103.0% |
| FY2021 | 2021-12-31 | 99.02M | — |
Debt Repayment vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -103.7% is the 6th highest of 9, against a peer median of -72.5%.
- Debt repayment amounts to 1.3% of revenue for ANIP, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹12.6B INR | +932.0% | — | 3.8% | |
| LTM Jun 2026 | $1.01B USD | -591.3% | -13.7% | 9.3% | |
| LTM Jun 2026 | $923.5M USD | -68.3% | — | 6.3% | |
| LTM Jun 2026 | $475.36M USD | -76.8% | +9.8% | 2.7% | |
| LTM Jun 2026 | $146.75M USD | +182.6% | — | 4.7% | |
| LTM Mar 2026 | $61.49M USD | -187.3% | — | 7.7% | |
| LTM Mar 2026 | $60.73M USD | +103.9% | -28.0% | 22.6% | |
| LTM Mar 2026 | $12.19M USD | -103.7% | +50.2% | 1.3% | |
| LTM Mar 2026 | $9.98M USD | — | — | 3.3% | |
| LTM Mar 2026 | $5.13M USD | — | -30.6% | 3.8% | |
| LTM Mar 2026 | $1.63M USD | -121.0% | — | 0.2% | |
| Peer median (excluding ANIP) | — | -72.5% | -20.9% | 4.3% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.6M) | (47.9M) | 18.78M | (18.52M) | 78.34M |
| Depreciation & Amortization | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| Deferred Income Tax | (16.75M) | (15.25M) | (11.74M) | (21.91M) | 14.24M |
| Stock-Based Compensation | 10.49M | 14.6M | 20.65M | 29.34M | 37.93M |
| Change in Working Capital | (84K) | (51.3M) | 24.86M | (11.19M) | (7.12M) |
| Accounts Receivables | (5.55M) | (36.91M) | 3.36M | (21.09M) | (58.53M) |
| Inventory | 3.22M | (23.63M) | (5.84M) | (21.29M) | (5.96M) |
| Accounts Payables | 10.17M | 5.04M | 7.55M | 479K | 15.16M |
| Other Working Capital | (7.93M) | 4.2M | 19.79M | 30.71M | 42.21M |
| Other Non-Cash Items | 5.02M | 8.99M | 6.62M | 18.56M | (29.57M) |
| Operating Cash Flow | 3.32M | (31.2M) | 118.96M | 64.02M | 185.23M |
| Capital Expenditures | (23.64M) | (16.46M) | (18.51M) | (16.95M) | (34.32M) |
| Acquisitions (Net) | (84.49M) | (33K) | 0 | (401.28M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (18.43M) | (6.83M) | (9.64M) | 12.8M | (20.49M) |
| Investing Cash Flow | (105.48M) | (15.74M) | (18.51M) | (404.72M) | (34.32M) |
| Debt Repayment | 99.02M | (3M) | (3M) | 345.22M | (10.16M) |
| Common Stock Issued | 69.58M | 0 | 80.56M | 0 | 13.6M |
| Common Stock Repurchased | (890K) | (1.96M) | (4.99M) | (10.96M) | (12.21M) |
| Dividends Paid | (190K) | (1.63M) | (1.63M) | (1.63M) | (1.16M) |
| Other Financing Activities | 2.07M | 1.46M | (3.5M) | (67.69M) | (26K) |
| Financing Cash Flow | 194.6M | (5.13M) | 67.44M | 264.95M | (9.94M) |
| Effect of Forex Changes | 0 | 0 | 0 | (470K) | (233K) |
| Net Change in Cash | 92.43M | (52.07M) | 167.89M | (76.23M) | 140.73M |
| Free Cash Flow | (20.32M) | (47.66M) | 100.45M | 47.06M | 150.9M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.